Inventor · disambiguated record
Ella Ioffe
Also filed as: IOFFE ELLA
18 granted patents·9 pending applications·236 citations·filing 1997–2024
93Inventor score
Top patents by PatentIndex Score
27 records- 0198US9987500B2Human antibodies to PD-1REGENERON PHARMA·Filed 2015·Granted Jun 5, 2018·126 cites·10 claims
- 0298US9938345B2Human antibodies to PD-L1REGENERON PHARMA·Filed 2015·Granted Apr 10, 2018·37 cites·8 claims
- 0396US10358495B2Anti-LAG3 antibodies and uses thereofREGENERON PHARMA·Filed 2016·Granted Jul 23, 2019·47 cites·18 claims
- 0493US11117970B2Human antibodies to PD-L1REGENERAN PHARMACEUTICALS INC·Filed 2018·Granted Sep 14, 2021·4 cites·15 claims
- 0589US10737113B2Human antibodies to PD-1REGENERON PHARMA·Filed 2018·Granted Aug 11, 2020·2 cites·18 claims
- 0689US9968674B2Methods and compositions comprising a combination of a VEGF Trap and an anti-CTLA-4 antibodyREGENERON PHARMA·Filed 2014·Granted May 15, 2018·10 cites·16 claims
- 0788US11692032B2Anti-LAG3 antibodies and uses thereofREGENERON PHARMA·Filed 2019·Granted Jul 4, 2023·3 cites·28 claims
- 0886US12389889B2Mouse having a humanized cluster of differentiation 47 geneREGENERON PHARMA·Filed 2024·Granted Aug 19, 2025·0 cites·9 claims
- 0985US10844137B2Anti-CTLA-4 antibodies and uses thereofREGENERON PHARMA·Filed 2018·Granted Nov 24, 2020·2 cites·20 claims
- 1084US10939673B2Method of using mouse having a humanized cluster of differentiation 47 geneREGENERON PHARMA·Filed 2018·Granted Mar 9, 2021·1 cites·7 claims
- 1184US2025092139A1Human antibodies to pd-l1REGENERON PHARMA·Filed 2024·Application pending·0 cites
- 1284US2024316361A1Human Antibodies To PD-1REGENERON PHARMA·Filed 2024·Application pending·0 cites
- 1383US2025122307A1Anti-CTLA-4 Antibodies and Uses ThereofREGENERON PHARMA·Filed 2024·Application pending·0 cites
- 1479US12187772B2IL10 agonists and methods of use thereofREGENERON PHARMA·Filed 2023·Granted Jan 7, 2025·0 cites·31 claims
- 1579US7812137B2Db, the receptor for leptin, nucleic acids encoding the receptor, and uses thereofUNIV ROCKEFELLER·Filed 2006·Granted Oct 12, 2010·1 cites·6 claims
- 1677US11910788B2Mouse having a humanized cluster of differentiation 47 geneREGENERON PHARMA·Filed 2021·Granted Feb 27, 2024·0 cites·12 claims
- 1777US2025333464A1Il10 agonists and methods of use thereofREGENERON PHARMA·Filed 2024·Application pending·0 cites
- 1877US2024166740A1Anti-lag3 antibodies and uses thereofREGENERON PHARMA·Filed 2023·Application pending·0 cites
- 1975US10015953B2Non-human animals having a humanized cluster of differentiation 47 geneREGENERON PHARMA·Filed 2016·Granted Jul 10, 2018·1 cites·7 claims
- 2074US2021380702A1Human antibodies to pd-l1REGENERON PHARMA·Filed 2021·Application pending·0 cites
- 2170US12024570B2Anti-CTLA-4 antibodies and uses thereofREGENERON PHARMA·Filed 2020·Granted Jul 2, 2024·0 cites·21 claims
- 2270US11673930B2IL10 agonists and methods of use thereofREGENERON PHARMA·Filed 2021·Granted Jun 13, 2023·0 cites·24 claims
- 2369US2020330794A1Human antibodies to pd-1REGENERON PHARMA·Filed 2020·Application pending·0 cites
- 2463US2023235089A1Methods for Treating Cancer with Bispecific Anti-CD3 x MUC16 Antibodies and Anti-CTLA-4 AntibodiesREGENERON PHARMA·Filed 2022·Application pending·0 cites
- 2558US10532096B2Methods and compositions comprising a combination of a VEGF antagonist and an anti-CTLA-4 antibodyREGENERON PHARMA·Filed 2018·Granted Jan 14, 2020·0 cites·32 claims
- 2656US2016345549A1Non-human animals having a humanized cluster of differentiation 47 geneREGENERON PHARMA·Filed 2015·Application pending·0 cites
- 2734US7148004B1Oligonucleotides of the OB-R isoforms and methods of diagnosing body weightUNIV ROCKEFELLER·Filed 1997·Granted Dec 12, 2006·2 cites·9 claims
Join the waitlist — get patent alerts
Get an alert when Ella Ioffe files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →